https://wikem.org/w/index.php?action=history&feed=atom&title=Budesonide%2FFormoterol 2026-05-02T17:47:47Z Revision history for this page on the wiki MediaWiki 1.38.2 https://wikem.org/w/index.php?title=Budesonide/Formoterol&diff=229045&oldid=prev 2019-09-19T21:37:48Z

<p></p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 21:37, 19 September 2019</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l110">Line 110:</td> <td colspan="2" class="diff-lineno">Line 110:</td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==References==</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>==References==</div></td></tr> <tr><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>&lt;references/&gt;</div></td><td class="diff-marker"></td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>&lt;references/&gt;</div></td></tr> <tr><td class="diff-marker" data-marker="−"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>[[Category:Pharmacology]]</div></td><td class="diff-marker" data-marker="+"></td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>[[Category:Pharmacology<ins style="font-weight: bold; text-decoration: none;">]] [[Category:Pulmonology</ins>]]</div></td></tr> </table>

ClaireLewis https://wikem.org/w/index.php?title=Budesonide/Formoterol&diff=111810&oldid=prev 2016-11-23T23:22:52Z

<p>Creation of page</p> <p><b>New page</b></p><div>==Administration==<br /> *Type: [[Inhaled corticosteroid]]<br /> *Dosage Forms: 80/4.5, 160/4.5 mcg/spray MDI<br /> *Routes of Administration: Inhaled<br /> *Common Trade Names: Symbicort<br /> <br /> ==Adult Dosing==<br /> *[[Asthma]], maintenance<br /> **2 puffs inhaled BID<br /> ***Start: Dependent on severity of asthma<br /> ***Max: 640 mcg/18 mcg/day<br /> ***May increase to 160 mcg/4.5 mcg/day per spray after 1-2 weeks if started at 80 mcg/4.5 mcg/spray.<br /> ***Taper to lowest effective dose.<br /> *[[COPD]], maintenance<br /> **2 puffs (160 mcg/4.5 mcg/ spray) inhaled BID<br /> ***Max: 640 mcg/18 mcg/day<br /> <br /> ==Pediatric Dosing==<br /> *5-11 yo<br /> **2 puffs inhaled BID<br /> ***Start: Dependent on severity of asthma<br /> ***Max: 320 mcg/18 mcg/day<br /> ***Taper to lowest effective dose. Use shortest effective treatment duration.<br /> *12+ yo<br /> **2 puffs inhaled BID<br /> ***Start: Dependent on severity of asthma<br /> ***Max: 640 mcg/18 mcg/day<br /> ***Taper to lowest effective dose. Use shortest effect treatment duration.<br /> <br /> ==Special Populations==<br /> *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C; Possible risk of delayed ossification based on animal data at 80x MRHD and risk with uterine contractility.<br /> *[[Lactation risk categories|Lactation risk]]: L3; Safety unknown<br /> <br /> ===Renal Dosing===<br /> *Adult: Not defined<br /> *Pediatric: Not defined<br /> <br /> ===Hepatic Dosing===<br /> *Adult: Not defined. Caution in severe hepatic impairment.<br /> *Pediatric: Not defined. Caution in severe hepatic impairment<br /> <br /> ==Contraindications==<br /> *Allergy to class/drug<br /> *[[Asthma]], acute<br /> *Bronchospasm, acute<br /> *[[COPD]], acute deteriorating<br /> <br /> ==Adverse Reactions==<br /> ===Serious===<br /> *Bronchospasm, paradoxial<br /> *[[Asthma]] exacerbation<br /> *Death, asthma-related<br /> *[[Pneumonia]]<br /> *Hypersensitivity Reaction<br /> *[[Anaphylaxis]]<br /> *[[Hypertension]]<br /> *[[Angina]]<br /> *[[Hypotension]]<br /> *[[Cardiac arrest]]<br /> *[[Arrhythmia]]<br /> *[[Hypokalemia]]<br /> *[[Hyperglycemia]]<br /> *[[Glaucoma]] in long-term use<br /> *Cataracts in long-term use<br /> *Osteoporosis in long-term use<br /> *Growth suppression in peds pts<br /> *Hypercorticism<br /> *Adrenal suppression<br /> *Behavioral distrubance<br /> <br /> ===Common===<br /> *Nasopharyngitis<br /> *[[Headache]]<br /> *[[URI]]<br /> *Pharyngolaryngeal pain<br /> *[[Sinusitis]]<br /> *[[Influenza]]<br /> *Back pain<br /> *Nasal congestion<br /> *[[Dyspepsia]]<br /> *[[Nausea]]<br /> *[[Vomiting]]<br /> *[[Candidiasis]], oral<br /> *BP changes<br /> *[[Chest pain]]<br /> *[[Palpitations]]<br /> *[[Tachycardia]]<br /> *Muscle cramps<br /> *Tremor<br /> *Nervousness<br /> *[[Insomnia]]<br /> *[[Cough]]<br /> *[[Bronchitis]]<br /> *Respiratory infection<br /> <br /> ==Pharmacology==<br /> *Half-life: Budesonide: 2.3 hr, Formoterol: 10 hr.<br /> *Metabolism: Budesonide: Liver, CYP450: 3A4 substreate. Formoterol: Liver extensively, CYP450: 2A6, 2C9/19, 2D6 substrate.<br /> *Excretion: Budesonide: Urine 60%, feces. Formoterol: Urine 59-62% (10% unchanged), feces 32-24%.<br /> <br /> ==Mechanism of Action==<br /> *Budesonide: Inhibits multiple inflammatory cytokine sand produces multiple glucocorticoid and mineralcorticoid effects. Exact mechanism unknown.<br /> *Formoterol: Selectively stimulates beta-2 adrenergic receptors, relaxing airway smooth muscle.<br /> <br /> ==Comments==<br /> Black Box Warning: Long acting beta-2 adrenergic agonists (LABA) increase risk of asthma-related death. LABA use may increase risk of asthma-related hospitalization in pediatric and adolescent patients. Do not use corticosteroid/LABA combo if asthma adequately controlled on low-or medium-dose inhaled corticosteroids.<br /> <br /> ==See Also==<br /> <br /> ==References==<br /> &lt;references/&gt;<br /> [[Category:Pharmacology]]</div>

Jonwarren